| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8fa73639d3e2c89ec8e445daf969b7ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_85359c3b6af0a3cb85a2a3c18954cc4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_71646f57eb8e2b7b544dc313ec3cb7ea |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 |
| filingDate |
1997-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc146ba3ef0e4234a26fc38e99dc7725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d04b7ec1691f8adc2ddc138b95e24e38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e346cf723fac6372f49664cd47b7c3e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_111ed2d35d59c2f1a804c41cc95109b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4580225d09dd8f43af9c7c51bb7ae376
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9ff945180fa205c23914659d0c1ac92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9afcd89ff9a782117537dbcf2a9bb64f |
| publicationDate |
1997-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2244864-A1 |
| titleOfInvention |
Methods for increasing endogenous levels of corticotropin-releasing factor |
| abstract |
Levels of free corticotropin-releasing factor (CRF) or CRF-related peptide are increased by administration to a patient of a ligand inhibitor of a CRF/CRF-binding protein complex or CRF-related peptide/CRF-binding protein complex. The ligand inhibitor binds to CRF-binding protein, thereby causing the release of CRF or increasing the level of the CRF-related peptide. The ligand inhibitor may be a peptide derived from CRF or a related protein or a non-peptide. Administration of the ligand inhibitor may provide improvement in learning and memory, in decreasing food intake or in providing treatment for diseases associated with low levels of CRF in the brain, notably Alzheimer's disease. A method is also provided for screening compounds to select particularly effective CRF antagonists for in vivo administration to mammals. |
| priorityDate |
1996-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |